Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA3 | P07451 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8038985 | 0.86 | GAA (0.68) | GAACA1CA2CA12CA3 | |
| SCHEMBL547554 | 0.86 | GAA (0.68) | GAACA1CA2CA12CA3 | |
| SCHEMBL1060443 | 0.81 | GAA (0.62) | GAACA1CA2CA12CA3 | |
| SCHEMBL28449841 | 0.81 | GAA (0.62) | GAACA1CA2CA12CA3 | |
| SCHEMBL1332797 | 0.79 | GAA (0.59) | GAACA1CA2CA12CA3 | |
| SCHEMBL664115 | 0.79 | GAA (0.59) | GAACA1CA2CA12CA3 | |
| SCHEMBL12807 | 0.78 | GAA (0.65) | GAACA1CA2CA12CA3 | |
| SCHEMBL28182477 | 0.78 | GAA (0.65) | GAACA1CA2CA12CA3 | |
| SCHEMBL11586425 | 0.77 | GAA (0.56) | GAACA1CA2CA12CA3 | |
| SCHEMBL9142919 | 0.77 | GAA (0.56) | GAACA1CA2CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011158248-A2 | PROCESS FOR PREPARATION OF POSACONAZOLE AND CRYSTALLINE POLYMORPHIC FORM V OF POSACONAZOLE | GLENMARK GENERICS LIMITED (IN) | 2011-12-22 | — | — | WO | claimed |
| US-20240160213-A1 | MAP DATA GENERATION DEVICE, STORAGE MEDIUM, AND MAP DATA GENERATION METHOD | CANON KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| US-11925690-B2 | Bifunctional molecules for targeting Rpn11 | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-03-12 | — | — | US | disclosed |
| CN-115368340-B | Oxime sulfonate photoacid generator, resist composition containing oxime sulfonate photoacid generator, electronic device and application of oxime sulfonate photoacid generator | 常州强力先端电子材料有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-115368341-B | Oxime sulfonate compound, resist composition containing oxime sulfonate compound, electronic device and application of oxime sulfonate compound | 常州强力先端电子材料有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20210283139-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | AMPHISTA THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| EP-3807272-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING RPN11 | Amphista Therapeutics Ltd (GB) | 2021-04-21 | — | — | EP | disclosed |
| EP-3807263-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | Amphista Therapeutics Ltd (GB) | 2021-04-21 | — | — | EP | disclosed |
| WO-2019238886-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING USP14 | UNIVERSITY OF DUNDEE (GB) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019238817-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING RPN11 | UNIVERSITY OF DUNDEE (GB) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019238816-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | UNIVERSITY OF DUNDEE (GB) | 2019-12-19 | — | — | WO | disclosed |
| US-9765019-B2 | Small-molecule-targeted protein degradation | BRANDEIS UNIVERSITY (US) | 2017-09-19 | — | — | US | disclosed |
| US-9408928-B2 | Compositions for targeted imaging and therapy | Radiomedix, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| CN-101516899-B | Compositions and methods for cellular imaging and therapy | 得克萨斯大学体系董事会 | 2016-07-06 | — | — | CN | disclosed |
| US-20130190340-A1 | Small-Molecule-Targeted Protein Degradation | BRANDEIS UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| US-8188287-B2 | Piperidyl acrylamide antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-29 | — | — | US | disclosed |
| US-20090087377-A1 | COMPOSITIONS FOR TARGETED IMAGING AND THERAPY | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2009-04-02 | — | — | US | disclosed |
| EP-0210804-B1 | PHOSPHATE ESTER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANKYO COMPANY LIMITED (JP) | 1989-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087377-A1 | COMPOSITIONS FOR TARGETED IMAGING AND THERAPY | EGFR, ASGR1, TK1 | GAA 193/4885CA1 916/4885CA2 2784/4885 |
| US-20210283139-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | UCHL5, UCHL3, UCHL1 | GAA 1008/4885CA1 4039/4885CA2 4667/4885 |
| US-20130190340-A1 | Small-Molecule-Targeted Protein Degradation | SMURF2, SMURF1, MDM2 | GAA 260/4885CA1 4084/4885CA2 4400/4885 |
| US-11925690-B2 | Bifunctional molecules for targeting Rpn11 | RPN1, RPP30, UBQLN1 | GAA 1165/4885CA1 4816/4885CA2 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.